Título
The establishment of cow’s milk protein allergy in infants is related with a deficit of regulatory T cells (Treg) and vitamin DAutor-a
Versión
PostprintTipo de documento
ArtículoIdioma
InglésDerechos
© 2017 International Pediatric Research Foundation, Inc.Acceso
Acceso abiertoVersión de la editorial
https://doi.org/10.1038/PR.2017.12Publicado en
Pediatric Research n. 5, vol. 81, n. art. 722Primera página
722Última página
830Editorial
Springer NaturePalabras clave
AllergyCalcium and vitamin D
Paediatric research
Regulatory T cells
Resumen
Background:
Cow’s milk protein allergy (CMPA) is the most common food allergy in infants. However, little is known about which specific immune mechanisms are related with the CMPA onset. The objectiv ... [+]
Background:
Cow’s milk protein allergy (CMPA) is the most common food allergy in infants. However, little is known about which specific immune mechanisms are related with the CMPA onset. The objective was to investigate which immune alterations constitute differential factors between allergy and tolerance, and hence could be implicated in the CMPA establishment in infants.
Methods:
An extensive analysis of immune subsets, including Treg and cytokine-secreting cells was performed in blood samples from 28 infants younger than 9 mo obtained 1–4 d after the first adverse reaction to milk.
Results:
Less than 4 d after first allergic reaction, infants who developed CMPA had decreased Treg counts and increased frequency of IL4-secreting CD4 T cells compared to controls. The deficit of Tregs was correlated with decreased serum levels of vitamin D. Values of Tregs, IL4-secreting cells and vitamin D were good predictors of CMPA diagnosis. Basal vitamin D levels in CMPA infants also predicted those CMPA patients developing spontaneous tolerance in the first year.
Conclusion:
Establishment of CMPA in infants was related with lower Treg and vitamin D levels. These immune alterations would be crucial factors behind the CMPA establishment and they could constitute a therapeutic target for treatment of CMPA. [-]
Financiador
Gobierno de EspañaISCIII
FEDER
Sociedad Española de Inmunología Clínica, Alergología y Asma Pediátrica (SEICAP)
Programa
Miguel Servet IIRamón y Cajal
FPU PhD
Número
CPII13/00033RYC-2009–05486
AP2012-2343



















